Mesoblast leads the pack with 8.7% share price gain
MELBOURNE: Stem cell treatments maker Mesoblast finished today’s session up 8.7 per cent to $1.93
MELBOURNE: Stem cell treatments maker Mesoblast finished today’s session up 8.7 per cent to $1.93
FEATURED
Supportive housing concept set to be launched Monday
Machine learning software platform for disability housing sector launched
Boomers being drawn to mixed-use developments on city regen sites
Looking at long term disability housing trends in 2024
Senior living ‘on precipice of this defining moment’ says CEO
Affordable and accessible homes for seniors now being designed
INNOVATION
